Association of serum trace elements with non-invasive fibrosis scores in metabolic dysfunction-associated steatotic liver disease

Liver biopsy is not a routine screening tool for detecting fibrosis progression in metabolic dysfunction-associated steatotic liver disease (MASLD). Noninvasive methods based on serum biomarkers are used instead. This study evaluated the relationship between serum zinc (Zn), copper (Cu), and ceruloplasmin levels and non-invasive criteria for hepatic fibrosis, including Fibrosis-4 (FIB-4), Nonalcoholic Fatty Liver Disease fibrosis score (NFS), and BARD, in patients with MASLD. In this prospective cross-sectional study, a total of 134 MASLD patients referred to the gastroenterology clinic of Imam Reza Hospital and Sheikh AlRaees Clinic, Tabriz, in 2022 were included. Serum levels of Zn, Cu, ceruloplasmin, albumin, complete blood count (CBC), fasting blood sugar (FBS), Alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were checked. Also, non-invasive measures of FIB-4, NFS, and BARD were measured. Finally, the relationship between the levels of Zn, Cu, and ceruloplasmin with each of the FIB-4, NFS, and BARD criteria was investigated. Zn serum levels were significantly lower in FIB-4 3 than in FIB-4 1 and 2 (P-value < 0.01); however, no significant relationship was found between serum Cu and ceruloplasmin variables with FIB-4 (P > 0.05). Zn serum levels were also significantly higher in NFS fibrosis score 1 (P-value < 0.01). There was no significant relationship between serum Cu and ceruloplasmin variables with NFS fibrosis score in the studied patients (P > 0.05). No significant relationship was observed between serum Zn, Cu, and ceruloplasmin with the BARD fibrosis score in the studied patients (P > 0.05). It seems that among the levels of Zn, Cu, and ceruloplasmin serum with non-invasive measures of liver fibrosis, including FIB-4, NFS, and BARD in MASLD patients, there is only a significant relationship between serum Zn level and FIB-4 and NFS criteria. And therefore, Zn may serve as a potential biomarker.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2025-09-25
DOI
https://doi.org/10.1038/s41598-025-16787-8
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Association of serum trace elements with non-invasive fibrosis scores in metabolic dysfunction-associated steatotic liver disease

Sina Hamzehzadeh, Zeinab Nikniaz, Erfan Banisefid, Seyedehyasmin Moghaddamziabari et al.
Scientific Reports
Liver Disease Diagnosis and Treatment
article

Association of serum trace elements with non-invasive fibrosis scores in metabolic dysfunction-associated steatotic liver disease

Sina Hamzehzadeh, Zeinab Nikniaz, Erfan Banisefid, Seyedehyasmin Moghaddamziabari, Leila Alizadeh, Sahand Karkon Zonouzi
article en

Abstract

Liver biopsy is not a routine screening tool for detecting fibrosis progression in metabolic dysfunction-associated steatotic liver disease (MASLD). Noninvasive methods based on serum biomarkers are used instead. This study evaluated the relationship between serum zinc (Zn), copper (Cu), and ceruloplasmin levels and non-invasive criteria for hepatic fibrosis, including Fibrosis-4 (FIB-4), Nonalcoholic Fatty Liver Disease fibrosis score (NFS), and BARD, in patients with MASLD. In this prospective cross-sectional study, a total of 134 MASLD patients referred to the gastroenterology clinic of Imam Reza Hospital and Sheikh AlRaees Clinic, Tabriz, in 2022 were included. Serum levels of Zn, Cu, ceruloplasmin, albumin, complete blood count (CBC), fasting blood sugar (FBS), Alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were checked. Also, non-invasive measures of FIB-4, NFS, and BARD were measured. Finally, the relationship between the levels of Zn, Cu, and ceruloplasmin with each of the FIB-4, NFS, and BARD criteria was investigated. Zn serum levels were significantly lower in FIB-4 3 than in FIB-4 1 and 2 (P-value < 0.01); however, no significant relationship was found between serum Cu and ceruloplasmin variables with FIB-4 (P > 0.05). Zn serum levels were also significantly higher in NFS fibrosis score 1 (P-value < 0.01). There was no significant relationship between serum Cu and ceruloplasmin variables with NFS fibrosis score in the studied patients (P > 0.05). No significant relationship was observed between serum Zn, Cu, and ceruloplasmin with the BARD fibrosis score in the studied patients (P > 0.05). It seems that among the levels of Zn, Cu, and ceruloplasmin serum with non-invasive measures of liver fibrosis, including FIB-4, NFS, and BARD in MASLD patients, there is only a significant relationship between serum Zn level and FIB-4 and NFS criteria. And therefore, Zn may serve as a potential biomarker.

Scientific ReportsVol. 15(1)
Tabriz University of Medical Sciences (IR), University of California, Davis (US)
Tabriz University of Medical Sciences, University of Tabriz
Openalex Percentile: Top 64%
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.